Revolution Medicines
RVMD · NASDAQ
$196.55+$14.40 (+7.91%)TodayMarket closed ·
Prev close $182.15
EPS: actual vs estimate
Didn’t beat the estimate in any of the last 8 quarters
Next report: , after the market closes
- Quarter
- Q3 FY26
- EPS estimate
- -$2.38
- Revenue estimate
- $26.31M
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$2.02 | -$3.06 | −51.7% |
| Q1 FY26 | -$1.88 | -$2.29 | −22.1% |
| Q4 FY25 | -$1.61 | -$1.86 | −15.4% |
| Q3 FY25 | -$1.45 | -$1.61 | −11.2% |
| Q2 FY25 | -$1.16 | -$1.31 | −12.8% |
| Q1 FY25 | -$1.11 | -$1.13 | −1.5% |
| Q4 FY24 | -$1.01 | -$1.12 | −11.3% |
| Q3 FY24 | -$0.9111 | -$0.94 | −3.2% |
Earnings calls
- Special Call - Revolution Medicines, Inc.
- RVMD - Earnings call Q2 2026
- Special Call - Revolution Medicines, Inc.
- RVMD - Earnings call Q1 2026
- TD Cowen 46th Annual Health Care Conference
- RVMD - Earnings call Q4 2025
- Guggenheim Securities Emerging Outlook: Biotech Summit 2026
- 44th Annual J.P. Morgan Healthcare Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.